01The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec ODT/Vydura, Oncology biosimilars and several other products across categoriesPadcev is being jointly developed and commercialized with Astellas in the U.S., with Pfizer having commercialization rights in all countries in North and South America
pipeline optionalitynot in the table